| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
90,552,000 |
| Market
Cap: |
7.00(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$36.19 - $86.25 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 557 |
| Guru Rank Value : 3.3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile PTC Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders. Co. has the following products, Translarna (ataluren) and Emflaza® (deflazacort), for the treatment of Duchenne muscular dystrophy, a rare, life threatening disorder. Co.'s gene therapy product candidates for rare monogenic diseases that affect the central nervous system (CNS) include PTC- Aromatic L-Amino Acid Decarboxylase (AADC) for the treatment of AADC deficiency, a rare CNS disorder arising from reductions in the enzyme AADC that results from mutations in the dopa decarboxylase gene.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
7,700 |
| Total Buy Value |
$0 |
$0 |
$0 |
$198,736 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
408,401 |
426,136 |
576,037 |
859,971 |
| Total Sell Value |
$28,645,946 |
$29,546,279 |
$37,208,492 |
$50,411,512 |
| Total People Sold |
7 |
8 |
11 |
13 |
| Total Sell Transactions |
20 |
24 |
65 |
100 |
| End Date |
2025-09-07 |
2025-06-06 |
2024-12-06 |
2023-12-07 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
Klein Matthew B. |
CHIEF EXECUTIVE OFFICER |
|
2025-12-02 |
4 |
S |
$79.07 |
$271,052 |
D/D |
(3,428) |
349,964 |
|
1% |
|
Klein Matthew B. |
CHIEF EXECUTIVE OFFICER |
|
2025-12-01 |
4 |
A |
$0.00 |
$0 |
D/D |
15,625 |
353,392 |
|
- |
|
Almstead Neil Gregory |
CHIEF TECHNICAL OPS OFFICER |
|
2025-11-25 |
4 |
AS |
$82.55 |
$6,001,932 |
D/D |
(71,928) |
100,625 |
|
-7% |
|
Almstead Neil Gregory |
CHIEF TECHNICAL OPS OFFICER |
|
2025-11-25 |
4 |
OE |
$18.01 |
$2,211,679 |
D/D |
71,928 |
112,024 |
|
- |
|
Jacobson Allan Steven |
|
|
2025-11-25 |
4 |
AS |
$82.58 |
$1,186,282 |
D/D |
(14,199) |
17,451 |
|
-7% |
|
Jacobson Allan Steven |
|
|
2025-11-25 |
4 |
OE |
$11.23 |
$213,017 |
D/D |
14,199 |
25,351 |
|
- |
|
Almstead Neil Gregory |
CHIEF TECHNICAL OPS OFFICER |
|
2025-11-24 |
4 |
AS |
$80.14 |
$2,852,031 |
D/D |
(35,572) |
100,625 |
|
-3% |
|
Almstead Neil Gregory |
CHIEF TECHNICAL OPS OFFICER |
|
2025-11-24 |
4 |
OE |
$18.01 |
$1,075,296 |
D/D |
35,572 |
106,726 |
|
- |
|
Jacobson Allan Steven |
|
|
2025-11-24 |
4 |
AS |
$80.13 |
$945,736 |
D/D |
(11,801) |
17,451 |
|
-3% |
|
Jacobson Allan Steven |
|
|
2025-11-24 |
4 |
OE |
$11.23 |
$173,883 |
D/D |
11,801 |
23,551 |
|
- |
|
Reeve Emma |
|
|
2025-11-21 |
4 |
AS |
$79.50 |
$795,000 |
D/D |
(10,000) |
6,666 |
|
-2% |
|
Reeve Emma |
|
|
2025-11-21 |
4 |
OE |
$51.16 |
$511,600 |
D/D |
10,000 |
16,666 |
|
- |
|
Okey Stephanie |
|
|
2025-11-20 |
4 |
GD |
$0.00 |
$0 |
D/D |
867 |
8,000 |
|
- |
|
Boulding Mark Elliott |
EXEC. VP AND CLO |
|
2025-11-17 |
4 |
AS |
$75.64 |
$213,687 |
D/D |
(2,812) |
103,901 |
|
2% |
|
Boulding Mark Elliott |
EXEC. VP AND CLO |
|
2025-11-17 |
4 |
OE |
$25.69 |
$72,240 |
D/D |
2,812 |
106,713 |
|
- |
|
Reeve Emma |
|
|
2025-11-12 |
4 |
AS |
$74.50 |
$546,309 |
D/D |
(7,333) |
6,666 |
|
3% |
|
Reeve Emma |
|
|
2025-11-12 |
4 |
OE |
$46.54 |
$341,278 |
D/D |
7,333 |
13,999 |
|
- |
|
Reeve Emma |
|
|
2025-10-30 |
4 |
AS |
$69.50 |
$1,088,787 |
D/D |
(15,666) |
6,666 |
|
13% |
|
Reeve Emma |
|
|
2025-10-30 |
4 |
OE |
$38.10 |
$457,200 |
D/D |
12,000 |
18,666 |
|
- |
|
Boulding Mark Elliott |
EXEC. VP AND CLO |
|
2025-10-07 |
4 |
AS |
$62.89 |
$214,091 |
D/D |
(3,375) |
103,901 |
|
21% |
|
Boulding Mark Elliott |
EXEC. VP AND CLO |
|
2025-10-07 |
4 |
OE |
$38.10 |
$128,588 |
D/D |
3,375 |
107,276 |
|
- |
|
Boulding Mark Elliott |
EXEC. VP AND CLO |
|
2025-10-06 |
4 |
AS |
$65.07 |
$147,449 |
D/D |
(2,266) |
103,901 |
|
19% |
|
Boulding Mark Elliott |
EXEC. VP AND CLO |
|
2025-10-06 |
4 |
OE |
$39.42 |
$89,326 |
D/D |
2,266 |
106,167 |
|
- |
|
Boulding Mark Elliott |
EXEC. VP AND CLO |
|
2025-10-03 |
4 |
AS |
$64.43 |
$1,491,100 |
D/D |
(22,655) |
103,901 |
|
18% |
|
Boulding Mark Elliott |
EXEC. VP AND CLO |
|
2025-10-03 |
4 |
OE |
$39.42 |
$893,060 |
D/D |
22,655 |
106,166 |
|
- |
|
565 Records found
|
|
Page 1 of 23 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|